Clinical Trial Update: Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of aldesleukin in combination with pembrolizumab in advanced or metastatic renal cell carcinoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Proleukin (aldesleukin)

Snippet

Sponsor: University of Washington | Conditions: Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-12-08